Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis

Liver International

Volumn 35, Issue 2, 2015, Pages 660-672

  Zachou, Kalliopi ^a   Gampeta, Stella ^a   Gatselis, Nikolaos K ^a   Oikonomou, Katerina ^a   Goulis, John ^b   Manoussakis, Menelaos N ^c   Renaudineau, Yves ^d   Bogdanos, Dimitrios P ^a,e   Dalekos, George N ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITÉ EUROPÉENNE DE BRETAGNE   (France)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anti Ro52 antibodies; Anti SLA LP antibodies; Autoimmune hepatitis; Sj gren's syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBODY; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RO52 ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; LIVER ANTIGEN LA-1; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; OLIGONUCLEOTIDE; RIBONUCLEOPROTEIN; SS-A ANTIGEN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HLA SYSTEM; HLA TYPING; HUMAN; IMMUNOBLOTTING; LIVER BIOPSY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CLASSIFICATION; GREECE; IMMUNOLOGY; KAPLAN MEIER METHOD; POLYMERASE CHAIN REACTION;

AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GREECE; HEPATITIS, AUTOIMMUNE; HUMANS; KAPLAN-MEIER ESTIMATE; MYCOPHENOLIC ACID; OLIGONUCLEOTIDES; POLYMERASE CHAIN REACTION; RIBONUCLEOPROTEINS;

EID: 84921518897     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12658     Document Type: Article

References (45)

1. Zachou K, Muratori P, Koukoulis GK, et al. Review article: autoimmune hepatitis - current management and challenges. Aliment Pharmacol Ther 2013; 38: 887-913.
2. Dalekos GN, Zachou K, Liaskos C, Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med 2002; 13: 293-303.
3. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76.
4. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol 2011; 55: 636-46.
5. Bogdanos DP, Dalekos GN. Enzymes as target antigens of liver-specific autoimmunity: the case of cytochromes P450. Curr Med Chem 2008; 15: 2285-92.
6. Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther 2012; 36: 691-707.
7. Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677-83.
8. Kanzler S, Weidemann C, Gerken G, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999; 31: 635-40.
9. Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000; 33: 208-15.
10. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterol 2010; 139: 58-72.
11. Efe C, Ozaslan E, Wahlin S, et al. Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study. Liver Int 2013; 33: 190-6.
12. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002; 51: 259-64.
13. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355: 1510-5.
14. Torres-Collado AX, Czaja AJ, Gelpi C. Anti t-RNP(ser)sec/SLA/LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs. Liver Int 2005; 25: 410-9.
15. Volkmann M, Luithle D, Zentgraf H, et al. SLA/LP/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. J Autoimmun 2010; 34: 59-65.
16. Herkel J, Heidrich B, Nieraad N, et al. Fine specificity of autoantibodies to soluble liver antigen and liver/pancreas. Hepatology 2002; 35: 403-8.
17. Mix H, Weiler-Normann C, Thimme R, et al. Identification of CD4 T-cell epitopes in soluble liver antigen/liver pancreas autoantigen in autoimmune hepatitis. Gastroenterology 2008; 135: 2107-18.
18. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413-9.
19. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity 2004; 37: 195-201.
20. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-64.
21. Liaskos C, Bogdanos DP, Rigopoulou EI, et al. Antibody responses specific for soluble liver antigen co-occur with Ro-52 autoantibodies in patients with autoimmune hepatitis. J Hepatol 2007; 46(Suppl. 1): S250.
22. Eyraud V, Chazouilleres O, Ballot E, et al. Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int 2009; 29: 857-64.
23. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 2012; 32: 85-92.
24. Schramm C, Herkel J, Beuers U, et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006; 101: 556-60.
25. Routsias JG, Tzioufas AG. B-cell epitopes of the intracellular autoantigens Ro/SSA and La/SSB: tools to study the regulation of the autoimmune response. J Autoimmun 2010; 35: 256-64.
26. Bournia VK, Vlachoyiannopoulos PG. Subgroups of Sjögren syndrome patients according to serological profiles. J Autoimmun 2012; 39: 15-26.
27. Retamozo S, Akasbi M, Brito-Zerón P, et al. Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome. Clin Exp Rheumatol 2012; 30: 686-92.
28. Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
29. Renaudineau Y, Dalekos GN, Guéguen P, Zachou K, Youinou P. Anti-α-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin Rev Allergy Immunol 2008; 34: 321-5.
30. Zachou K, Oikonomou K, Renaudineau Y, et al. Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. Aliment Pharmacol Ther 2012; 35: 116-25.
31. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
32. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
33. Georgiadou SP, Zachou K, Liaskos C, et al. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int 2009; 29: 434-42.
34. Gatselis NK, Zachou K, Norman GL, et al. IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. Clin Chim Acta 2012; 413: 1683-8.
35. Dalekos GN, Makri E, Loges S, et al. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of HCV patients from central Greece. Eur J Gastroenterol Hepatol 2002; 14: 35-42.
36. Gatselis NK, Georgiadou SP, Koukoulis GK, et al. Clinical significance of organ and non-organ specific autoantibodies on the response to antiviral treatment of patients with chronic hepatitis C. Aliment Pharmacol Ther 2006; 24: 1563-73.
37. Dalekos GN, Wedemeyer H, Obermayer-Straub P, et al. Epitope mapping of cytochrome P450 2D6 autoantigen in patients with chronic hepatitis C under α-interferon treatment. J Hepatol 1999; 30: 366-75.
38. Granito A, Muratori P, Muratori L, et al. Antibodies to SS-A/Ro52kD and centromere in autoimmune liver disease; a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther 2007; 26: 831-8.
39. Kvarnström M, Dzikaite-Ottosson V, Ottosson L, et al. Autoantibodies to the functionally active RING-domain of Ro52/SSA are associated with disease activity in patients with lupus. Lupus 2013; 22: 477-85.
40. Espinosa A, Hennig J, Ambrosi A, et al. Anti-Ro52 autoantibodies from patients with Sjogren's syndrome inhibit the Ro52 E3 ligase activity by blocking the E3/E2 interface. J Biol Chem 2011; 286: 36478-91.
41. Espinosa A, Dardalhon V, Brauner S, et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med 2009; 206: 1661-71.
42. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6: 379-88.
43. Oke V, Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun 2012; 39: 77-82.
44. Moutsopoulos NM, Routsias JG, Vlachoyiannopoulos PG, Tzioufas AG, Moutsopoulos HM. B-cell epitopes of intracellular autoantigens: myth and reality. Mol Med 2000; 6: 141-51.
45. Dorner T, Feist E, Held C, et al. Differential recognition of the 52-kd Ro(SS-A) antigen by sera from patients with primary biliary cirrhosis and primary Sjögren's syndrome. Hepatology 1996; 24: 1404-7.